4.7 Article

A stratified model for health outcomes in ankylosing spondylitis

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 70, 期 10, 页码 1758-1764

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2011.150037

关键词

-

资金

  1. Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/62329/2009]
  2. Fundação para a Ciência e a Tecnologia [SFRH/BD/62329/2009] Funding Source: FCT

向作者/读者索取更多资源

Objective To investigate the relationships between several health outcomes in ankylosing spondylitis (AS). Methods Baseline pretreatment data from 214 patients with AS participating in the AS Study for the Evaluation of Recombinant Infliximab Therapy were analysed. Measures of health-related quality of life (HRQoL) and physical function were used as dependent variables in linear regression analysis. Associations between HRQoL (36-Item Short Form (SF-36)), physical function, clinical disease activity, spinal mobility, structural damage, MRI inflammation, disease duration, age, gender, body mass index and HLA-B27 were explored. Univariate associations were retested in multivariate models. The robustness of the models was evaluated by sensitivity analyses. Results The physical component of SF-36 was independently associated with measures of physical function and disease activity (adjusted R 2 (adjR 2)= 0.39-0.40). The mental component of SF-36 was independently associated with physical function (adjR 2 = 0.07). Physical function was independently associated with measures of spinal mobility and disease activity (adjR 2 = 0.39-0.45). Spinal mobility was hierarchically shown to be an intermediate variable between structural damage and physical function, while physical function was shown to be intermediate between spinal mobility and the physical component of SF-36. Conclusion According to the proposed stratified model for health outcomes in AS, HRQoL is determined by physical function and disease activity, physical function is determined by spinal mobility and disease activity, and spinal mobility is determined by structural damage and inflammation of the spine. As more is learnt about how to measure AS, knowledge about the disease improves and better decisions can be made on the assessment and treatment of this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial

T. Rusman, M. A. C. van der Weijden, M. T. Nurmohamed, C. J. van Denderen, R. B. M. Landewe, P. M. Bet, C. M. A. van der Bijl, C. J. Van der Laken, I. E. van der Horst-Bruinsma

Summary: The study found that 16 weeks of etanercept treatment did not have an impact on disease activity, the chance of biological treatment, or radiographic progression in patients with suspected non-radiographic axial spondyloarthritis.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Health Care Sciences & Services

Health-related quality of life among spondyloarthritis and chronic low back pain patients: results from a nationwide population-based survey

Helena Santos, Ana Rita Henriques, Jaime Branco, Pedro M. Machado, Helena Canhao, Fernando M. Pimentel-Santos, Ana Maria Rodrigues

Summary: The study found that both spondyloarthritis and chronic low back pain have similar impacts on health-related quality of life (HRQoL), including mental, physical, and social domains. Patients with spondyloarthritis and chronic low back pain reported significantly lower HRQoL compared to those without rheumatic diseases. Modifiable factors such as multimorbidity, active disease, obesity, and regular physical exercise were associated with HRQoL in these conditions.

QUALITY OF LIFE RESEARCH (2023)

Review Rheumatology

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro

Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.

RHEUMATOLOGY (2023)

Article Rheumatology

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen

Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.

RHEUMATOLOGY (2023)

Article Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen, Robert B. M. Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L. Hyrich, Janet E. Pope, Savia de Souza, Tanja A. Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L. Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H. Buch, Gerd R. Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A. den Broeder, Khadija El Aoufy, Axel Finckh, Joao Eurico Fonseca, Jacques-Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo F. Mysler, Peter Nash, Gyula Poor, Gorica G. Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P. M. Vliet Vlieland, Rene Westhovens, Desiree van der Heijde

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Global Perspective on the Impact of the COVID-19 Pandemic on Rheumatology and Health Equity

Evelyn Hsieh, Dzifa Dey, Rebecca Grainger, Mengtao Li, Pedro M. Machado, Manuel F. Ugarte-Gil, Jinoos Yazdany

Summary: Although the public health emergency associated with the COVID-19 pandemic has ended, challenges remain for individuals with rheumatic diseases. Disruptions in healthcare and medication supply shortages have impacted the health and mental well-being of these individuals. Telemedicine and changes in healthcare utilization have also affected rheumatology practices globally. Efforts are needed to improve healthcare access, stabilize rheumatology drug supplies, and implement evidence-based vaccination practices to reduce COVID-19 morbidity and mortality among individuals with rheumatic diseases.

ARTHRITIS CARE & RESEARCH (2023)

Article Medicine, General & Internal

Proof-of-Concept Double-Blind Placebo-Controlled Trial Measuring Cartilage Composition in Early Rheumatoid Arthritis under TNF-α-Inhibitor Therapy

Miriam Frenken, Benedikt Ostendorf, Ralph Brinks, Christoph Schleich, Lena M. Wilms, Stefan Vordenbaeumen, Anja Mueller-Lutz, Jutta G. Richter, Oliver Sander, Gerald Antoch, Matthias Schneider, Xenofon Baraliakos, Daniel B. Abrar, Philipp Sewerin

Summary: This study evaluated the effect of combination therapy with methotrexate and adalimumab versus methotrexate alone on cartilage status in patients with early rheumatoid arthritis using delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC). The results showed that combination therapy resulted in improved cartilage composition, while methotrexate alone did not have any effect on cartilage composition.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Rheumatology

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler

Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Pharmacology & Pharmacy

Janus kinase-inhibition modulates hepatitis E virus infection

Volker Kinast, Ioana Andreica, Gerrit Ahrenstorf, Andre Goemer, Carina Elsner, Sarah Schlienkamp, Jil Alexandra Schrader, Mara Klohn, Rainer G. Ulrich, Ruth Broering, Florian W. R. Vondran, Daniel Todt, Patrick Behrendt, Ulf Dittmer, Axel Hamprecht, Torsten Witte, Xenofon Baraliakos, Eike Steinmann

Summary: This study aimed to investigate the influence of JAK inhibitors on HEV replication. The results showed that JAKi treatment increased HEV replication and disrupted the immune response triggered by HEV. Therefore, monitoring potential HEV infections is necessary during JAKi treatment and when liver enzymes are elevated.

ANTIVIRAL RESEARCH (2023)

Letter Rheumatology

Comment on: MRI characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort: Reply

Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro-Compan, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe

RHEUMATOLOGY (2023)

暂无数据